Switch from premixed insulin analogue to degludec-liraglutide combination: a CGM study.

Front Endocrinol (Lausanne) · 2025 · PMC12626799 · PMID 41268167

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While numerical reductions in hypoglycemia did not reach statistical significance, treatment was not associated with an increased risk of hypoglycemia. iDegLira can be an efficient and safe treatment option, providing simplified treatment with improved glycemic control.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.